In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 231 to 240 of 294

TitleTypeExpected publication date
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]Technology appraisal guidanceTBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]Technology appraisal guidanceTBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]Technology appraisal guidanceTBC
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Technology appraisal guidance
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]Technology appraisal guidanceTBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]Technology appraisal guidanceTBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]Technology appraisal guidance
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All